NASDAQ · RANI
Rani Therapeutics Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RANI: Nov 5, 2026
Rani Therapeutics Holdings, Inc. Class A Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Dec 2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · BNK Invest · NASDAQ.com- MarketBeat · Oct 21, 10:02 PM EDTRani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform AdvancesRani Therapeutics (NASDAQ:RANI) outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai. Chief Executive Officer Talat Imran said the clinical-
- RTTNews · Oct 5, 10:42 AM EDTRani Therapeutics' RaniPill Accepted Into FDA Emerging Technology Program(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI) on Monday announced that its RaniPill Capsule platform technology has been accepted into the U.S. FDA's Emerging Technology Program (ETP).
- RTTNews · Aug 27, 7:27 AM EDTRani Therapeutics Reports Q2 Update; RT-114 Expansion Data Expected By Year-End(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI) recently reported its second-quarter 2026 financial results, reflecting a narrower net loss, new contract revenue and continued progress across its oral biologics pipeline.
- MarketBeat · Aug 16, 4:01 PM EDTRani Therapeutics Expands Oral Biologics Push With Obesity, Immunology PipelineRani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity. Chief Executive Officer Talat Imran
- BNK Invest · Jul 22, 10:31 AM EDTWednesday 7/22 Insider Buying Report: CAG, RANIBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- RTTNews · Jul 15, 9:01 AM EDTRani's RT-114 Oral Capsule Shows Strong Bioavailability In Phase 1a Study; Phase 1b Underway(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI) announced positive initial data from its ongoing Phase 1a study of RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
- RTTNews · Jul 15, 8:46 AM EDTRani Therapeutics Reports Positive Initial Phase 1 Data For RT-114(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI) on Wednesday reported positive initial data from the Phase 1 study of RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen Co., Ltd.
- RTTNews · Jul 10, 1:57 AM EDTRani Therapeutics, PegBio Ink R&D Deal For Obesity, Metabolic Disease Candidates(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced a research and development collaboration with PegBio Co., Ltd. to evaluate multiple candidates from PegBio's obesity and metabolic disease pipeline using Rani's proprietary Ra
- RTTNews · Jun 30, 1:44 AM EDTRani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. He succeeds Svai Sanford, who announced his departure in May 2026 to pursue professional
- RTTNews · Jun 29, 9:00 AM EDTRani Therapeutics CFO Svai Sanford Steps Down, Nicholas Maestas Appointed As Successor(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI) said on Monday that Chief Financial Officer Svai Sanford has stepped down. Following this, the company has appointed Nicholas Maestas as successor, effective immediately.
- RTTNews · May 26, 11:46 AM EDTRani Announces Pricing Of $20 Mln Direct Offering At $1.07 Per Share; Stock Down(RTTNews) – Rani Therapeutics Holdings Inc. (RANI), a clinical-stage biotherapeutics company, on Tuesday announced pricing of a registered direct offering worth $20 million.
- NASDAQ.com · Mar 26, 2:00 PM EDTAfter-Hours Earnings Report for March 26, 2026 : AGX, OXM, VERI, BAK, ACOG, RANI, SLND, VTSI, WPRT, LSF, XOS, DAREThe following companies are expected to report earnings after hours on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Argan, Inc. (AGX)is reporting for the quarter ending January 31, 2026. The building company's consensus earnings per share
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rani Therapeutics Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.